iMMagine-3
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
Filters
Save & Share
Clear Filters
Location
Explore options near your patient - or anywhere in the US.
Diagnosis
Treatment History
BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Near Add Your Location
Sorting 10 by
- Accepting patients
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Accepting patients
Baptist Cancer Center Memphis
Mempis, TN
- Accepting patients
UCSF Helen Diller Comprehensive Cancer Center
University of California San Francisco
San Francisco, CA
- Accepting patients
- Accepting patients
Massachusetts General Hospital
Boston, MA
- Accepting patients
Boston Medical Center
Boston, MA
- Accepting patients
Swedish Medical Center (Ballard Campus)
Seattle, WA
- Accepting patients
1,370 hidden based on your filters. Show All
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.